Antimitochondrial antibodies in acute liver failure

Implications for primary biliary cirrhosis

Patrick S C Leung, Lorenzo Rossaro, Paul A. Davis, Ogyi Park, Atsushi Tanaka, Kentaro Kikuchi, Hiroshi Miyakawa, Gary L. Norman, William Lee, M. Eric Gershwin, W. M. Lee, Julie Polson, Carla Pezzia, Anne Larson, Timothy Davern, Paul Martin, Timothy McCashland, J. Eileen Hay, Natalie Murray, A. Obaid Shakil & 14 others Andres Blei, Atif Zaman, Steven Han, Robert Fontana, Brendan McGuire, Ray Chung, Alastair Smith, Michael Schilsky, Adrian Reuben, Santiago Munoz, Rajender Reddy, R. Todd Stravitz, Raj Satyanarayana, Tarek Hassanein

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

In our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6%) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1% of ALF patients). Conclusion: The strikingly high frequency of AMAs in ALF supports the thesis that oxidative stress-induced liver damage may lead to AMA induction. The rapid disappearance of AMAs in these patients provides further support for the contention that PBC pathogenesis requires additional factors, including genetic susceptibility.

Original languageEnglish (US)
Pages (from-to)1436-1442
Number of pages7
JournalHepatology
Volume46
Issue number5
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Acute Liver Failure
Biliary Liver Cirrhosis
Autoantibodies
Antibodies
Autoantigens
Oxidoreductases
Glutarates
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Serum
Gliadin
Centromere
Liver
Xenobiotics
Genetic Predisposition to Disease
Pyruvic Acid
Oxidants
Chromatin
Liver Diseases
Oxidative Stress
Peptides

ASJC Scopus subject areas

  • Hepatology

Cite this

Leung, P. S. C., Rossaro, L., Davis, P. A., Park, O., Tanaka, A., Kikuchi, K., ... Hassanein, T. (2007). Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology, 46(5), 1436-1442. https://doi.org/10.1002/hep.21828

Antimitochondrial antibodies in acute liver failure : Implications for primary biliary cirrhosis. / Leung, Patrick S C; Rossaro, Lorenzo; Davis, Paul A.; Park, Ogyi; Tanaka, Atsushi; Kikuchi, Kentaro; Miyakawa, Hiroshi; Norman, Gary L.; Lee, William; Gershwin, M. Eric; Lee, W. M.; Polson, Julie; Pezzia, Carla; Larson, Anne; Davern, Timothy; Martin, Paul; McCashland, Timothy; Hay, J. Eileen; Murray, Natalie; Shakil, A. Obaid; Blei, Andres; Zaman, Atif; Han, Steven; Fontana, Robert; McGuire, Brendan; Chung, Ray; Smith, Alastair; Schilsky, Michael; Reuben, Adrian; Munoz, Santiago; Reddy, Rajender; Stravitz, R. Todd; Satyanarayana, Raj; Hassanein, Tarek.

In: Hepatology, Vol. 46, No. 5, 11.2007, p. 1436-1442.

Research output: Contribution to journalArticle

Leung, PSC, Rossaro, L, Davis, PA, Park, O, Tanaka, A, Kikuchi, K, Miyakawa, H, Norman, GL, Lee, W, Gershwin, ME, Lee, WM, Polson, J, Pezzia, C, Larson, A, Davern, T, Martin, P, McCashland, T, Hay, JE, Murray, N, Shakil, AO, Blei, A, Zaman, A, Han, S, Fontana, R, McGuire, B, Chung, R, Smith, A, Schilsky, M, Reuben, A, Munoz, S, Reddy, R, Stravitz, RT, Satyanarayana, R & Hassanein, T 2007, 'Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis', Hepatology, vol. 46, no. 5, pp. 1436-1442. https://doi.org/10.1002/hep.21828
Leung PSC, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K et al. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology. 2007 Nov;46(5):1436-1442. https://doi.org/10.1002/hep.21828
Leung, Patrick S C ; Rossaro, Lorenzo ; Davis, Paul A. ; Park, Ogyi ; Tanaka, Atsushi ; Kikuchi, Kentaro ; Miyakawa, Hiroshi ; Norman, Gary L. ; Lee, William ; Gershwin, M. Eric ; Lee, W. M. ; Polson, Julie ; Pezzia, Carla ; Larson, Anne ; Davern, Timothy ; Martin, Paul ; McCashland, Timothy ; Hay, J. Eileen ; Murray, Natalie ; Shakil, A. Obaid ; Blei, Andres ; Zaman, Atif ; Han, Steven ; Fontana, Robert ; McGuire, Brendan ; Chung, Ray ; Smith, Alastair ; Schilsky, Michael ; Reuben, Adrian ; Munoz, Santiago ; Reddy, Rajender ; Stravitz, R. Todd ; Satyanarayana, Raj ; Hassanein, Tarek. / Antimitochondrial antibodies in acute liver failure : Implications for primary biliary cirrhosis. In: Hepatology. 2007 ; Vol. 46, No. 5. pp. 1436-1442.
@article{19968b87b0104510867bff66f135cf4a,
title = "Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis",
abstract = "In our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6{\%}) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1{\%} of ALF patients). Conclusion: The strikingly high frequency of AMAs in ALF supports the thesis that oxidative stress-induced liver damage may lead to AMA induction. The rapid disappearance of AMAs in these patients provides further support for the contention that PBC pathogenesis requires additional factors, including genetic susceptibility.",
author = "Leung, {Patrick S C} and Lorenzo Rossaro and Davis, {Paul A.} and Ogyi Park and Atsushi Tanaka and Kentaro Kikuchi and Hiroshi Miyakawa and Norman, {Gary L.} and William Lee and Gershwin, {M. Eric} and Lee, {W. M.} and Julie Polson and Carla Pezzia and Anne Larson and Timothy Davern and Paul Martin and Timothy McCashland and Hay, {J. Eileen} and Natalie Murray and Shakil, {A. Obaid} and Andres Blei and Atif Zaman and Steven Han and Robert Fontana and Brendan McGuire and Ray Chung and Alastair Smith and Michael Schilsky and Adrian Reuben and Santiago Munoz and Rajender Reddy and Stravitz, {R. Todd} and Raj Satyanarayana and Tarek Hassanein",
year = "2007",
month = "11",
doi = "10.1002/hep.21828",
language = "English (US)",
volume = "46",
pages = "1436--1442",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Antimitochondrial antibodies in acute liver failure

T2 - Implications for primary biliary cirrhosis

AU - Leung, Patrick S C

AU - Rossaro, Lorenzo

AU - Davis, Paul A.

AU - Park, Ogyi

AU - Tanaka, Atsushi

AU - Kikuchi, Kentaro

AU - Miyakawa, Hiroshi

AU - Norman, Gary L.

AU - Lee, William

AU - Gershwin, M. Eric

AU - Lee, W. M.

AU - Polson, Julie

AU - Pezzia, Carla

AU - Larson, Anne

AU - Davern, Timothy

AU - Martin, Paul

AU - McCashland, Timothy

AU - Hay, J. Eileen

AU - Murray, Natalie

AU - Shakil, A. Obaid

AU - Blei, Andres

AU - Zaman, Atif

AU - Han, Steven

AU - Fontana, Robert

AU - McGuire, Brendan

AU - Chung, Ray

AU - Smith, Alastair

AU - Schilsky, Michael

AU - Reuben, Adrian

AU - Munoz, Santiago

AU - Reddy, Rajender

AU - Stravitz, R. Todd

AU - Satyanarayana, Raj

AU - Hassanein, Tarek

PY - 2007/11

Y1 - 2007/11

N2 - In our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6%) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1% of ALF patients). Conclusion: The strikingly high frequency of AMAs in ALF supports the thesis that oxidative stress-induced liver damage may lead to AMA induction. The rapid disappearance of AMAs in these patients provides further support for the contention that PBC pathogenesis requires additional factors, including genetic susceptibility.

AB - In our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6%) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1% of ALF patients). Conclusion: The strikingly high frequency of AMAs in ALF supports the thesis that oxidative stress-induced liver damage may lead to AMA induction. The rapid disappearance of AMAs in these patients provides further support for the contention that PBC pathogenesis requires additional factors, including genetic susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=36348950863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348950863&partnerID=8YFLogxK

U2 - 10.1002/hep.21828

DO - 10.1002/hep.21828

M3 - Article

VL - 46

SP - 1436

EP - 1442

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -